AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34634256 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax 800 mg
Number of subjects: 30
Study 34634256 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax with dose-adjusted EPOCH-R
Number of subjects: 30
Study 34634438 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) delivered to the whole breast to 45 to 50 Gy in standard daily fractions of 1.8 to 2.0 Gy, with a mandatory boost of 10 to 16 Gy in 2.0-Gy daily fractions to each tumor bed.
Number of subjects: 236
Study 34634512 — intervention group
Group type: EXPERIMENTAL
Intervention: School breakfast consumers (SBC)
Number of subjects: 383
Study 34634754 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly electronic PRO symptom monitoring for 12 months
Number of subjects: 118
Study 34635048 — intervention group
Group type: EXPERIMENTAL
Intervention: DINOSAUR (DINO Strategies for Anxiety and Intolerance of Uncertainty Reduction), a 12-week group telehealth treatment
Number of subjects: 0
Study 34635048 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 34635048 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions targeting intolerance of uncertainty (IU) and parental accommodation
Number of subjects: 0
Study 34635128 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low tidal ventilation (4 mL/kg)
Number of subjects: 0
Study 34635128 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard tidal volume)
Number of subjects: 0
Study 34635151 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic sepsis alert
Number of subjects: 65250
Study 34635151 — intervention group
Group type: COMPARATOR
Intervention: No alert (masked alert)
Number of subjects: 65250
Study 34635169 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia risk communication strategies
Number of subjects: 0
Study 34635169 — intervention group
Group type: EXPERIMENTAL
Intervention: Different approaches to risk communication
Number of subjects: 0
Study 34635169 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based dementia risk communication protocol
Number of subjects: 0
Study 34635169 — intervention group
Group type: EXPERIMENTAL
Intervention: E-tools for dementia risk communication
Number of subjects: 0
Study 34635208 — intervention group
Group type: EXPERIMENTAL
Intervention: UHPLC-ESI-QqQ-MS/MS method for GLP-1 and GIP detection
Number of subjects: 20
Study 34635208 — intervention group
Group type: EXPERIMENTAL
Intervention: OASIS HLB SPE cartridge
Number of subjects: 20
Study 34635208 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trial validation
Number of subjects: 20
Study 34635518 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional preparedness
Number of subjects: 484
Study 34635518 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological preparedness
Number of subjects: 484
Study 34635518 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with preparedness
Number of subjects: 484
Study 34635525 — intervention group
Group type: EXPERIMENTAL
Intervention: ENT clinical assessment and management of ENT disease in patients with PCD
Number of subjects: 0
Study 34635525 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported data on clinical symptoms and health-related quality of life (QoL)
Number of subjects: 0
Study 34635525 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic test results and results of ENT examinations
Number of subjects: 0
Study 34635525 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung function measurements
Number of subjects: 0
Study 34635529 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced AMS programme (including telephonic discussions with ID experts and biweekly meetings)
Number of subjects: 147644
Study 34635529 — intervention group
Group type: COMPARATOR
Intervention: Standard AMS programme
Number of subjects: 147644
Study 34635529 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced AMS programme
Number of subjects: 147644
Study 34635537 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression reduction combined with a third BNT162b2 vaccine dose
Number of subjects: 154
Study 34635537 — intervention group
Group type: COMPARATOR
Intervention: Third BNT162b2 vaccine dose alone
Number of subjects: 154
Study 34635577 — intervention group
Group type: EXPERIMENTAL
Intervention: FAMCAT 1 algorithm
Number of subjects: 260
Study 34635577 — intervention group
Group type: EXPERIMENTAL
Intervention: FAMCAT 2 algorithm
Number of subjects: 260
Study 34635577 — intervention group
Group type: EXPERIMENTAL
Intervention: DLCN score ≥6 points
Number of subjects: 260
Study 34635577 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended cholesterol thresholds
Number of subjects: 260
Study 34635577 — intervention group
Group type: EXPERIMENTAL
Intervention: Simon-Broome criteria
Number of subjects: 260
Study 34636000 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg once daily
Number of subjects: 0
Study 34636000 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib monotherapy
Number of subjects: 0
Study 34636026 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 0
Study 34636026 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 0
Study 34636026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34636026 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg
Number of subjects: 0
Study 34636226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative infusion of esmolol
Number of subjects: 0
Study 34636226 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34636319 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe OSA
Number of subjects: 58
Study 34636627 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223
Number of subjects: 346
Study 34636627 — intervention group
Group type: COMPARATOR
Intervention: Alternative NHT
Number of subjects: 346
Study 34636637 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutation carriers
Number of subjects: 68
Study 34637072 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegAsp treatment initiated at physicians' discretion
Number of subjects: 1112
Study 34637082 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34637140 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time B-mode ultrasound guidance
Number of subjects: 7997
Study 34637140 — intervention group
Group type: EXPERIMENTAL
Intervention: In-plane real-time B-mode ultrasound guidance
Number of subjects: 7997
Study 34637140 — intervention group
Group type: COMPARATOR
Intervention: DUA
Number of subjects: 7997
Study 34637140 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique-axis in-plane B-mode ultrasound guidance
Number of subjects: 7997
Study 34637151 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg oral dose
Number of subjects: 23
Study 34637337 — intervention group
Group type: EXPERIMENTAL
Intervention: mammalian target of rapamycin inhibitor
Number of subjects: 34
Study 34637497 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (aHEI-2010)
Number of subjects: 2694
Study 34637497 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Approaches to Stop Hypertension diet
Number of subjects: 2694
Study 34637497 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating Index-2015
Number of subjects: 2694
Study 34637497 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative Mediterranean diet
Number of subjects: 2694
Study 34637506 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly growth measurement between 9 and 11 months
Number of subjects: 5039
Study 34637506 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual regression of length on age
Number of subjects: 5039
Study 34637506 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiencing 2 consecutive months of slow growth (<15th centile)
Number of subjects: 5039
Study 34637527 — intervention group
Group type: COMPARATOR
Intervention: Music interventions (music therapy and music medicine)
Number of subjects: 5576
Study 34637573 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever-smoker recipients
Number of subjects: 858
Study 34637573 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking history >20 pack-years
Number of subjects: 858
Study 34637573 — intervention group
Group type: COMPARATOR
Intervention: Donor smoking status
Number of subjects: 858
Study 34637573 — intervention group
Group type: COMPARATOR
Intervention: Recipient and donor smoking status
Number of subjects: 858
Study 34638132 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y-antiCD25 (aTac) with BEAM AHCT
Number of subjects: 25
Study 34638132 — intervention group
Group type: COMPARATOR
Intervention: Standard AHCT
Number of subjects: 25
Study 34638136 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib, 160 mg, twice-daily oral administration until disease progression or unacceptable toxicity
Number of subjects: 41
Study 34638136 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 41
Study 34638225 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg every 3 weeks for up to 15 months) combined with standard carboplatin-paclitaxel
Number of subjects: 824
Study 34638225 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg every 3 weeks for up to 15 months)
Number of subjects: 824
Study 34638369 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant ado-trastuzumab emtansine (T-DM1) for 12 weeks
Number of subjects: 0
Study 34638369 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant ado-trastuzumab emtansine (T-DM1) ± endocrine therapy
Number of subjects: 0
Study 34640562 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR positive patients (influenza or RSV)
Number of subjects: 803
Study 34640562 — intervention group
Group type: COMPARATOR
Intervention: Patients without flu-like symptoms
Number of subjects: 803
Study 34641803 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component Cognitive Intervention using Simulated Everyday Tasks (MCI-SET)
Number of subjects: 130
Study 34641806 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT)
Number of subjects: 30
Study 34641820 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation and/or treatment of parasitic infections
Number of subjects: 760
Study 34641820 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 760
Study 34641896 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral (DAA) treatment
Number of subjects: 60
Study 34641956 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue biopsies for TMB assessment
Number of subjects: 202
Study 34641956 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 202
Study 34642197 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 104
Study 34642329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab and nivolumab
Number of subjects: 18
Study 34642428 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) with gadolinium administration prior to surgical aortic valve replacement
Number of subjects: 250
Study 34642699 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 25 μg
Number of subjects: 30
Study 34642699 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 100 μg
Number of subjects: 30
Study 34642699 — intervention group
Group type: EXPERIMENTAL
Intervention: ACOV2S
Number of subjects: 30
Study 34643344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US)
Number of subjects: 2
Study 34643344 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic palpation
Number of subjects: 2
Study 34643344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) at T4
Number of subjects: 2
Study 34643344 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic palpation at T4
Number of subjects: 2
Study 34643344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) at T5
Number of subjects: 2
Study 34643344 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic palpation at T5
Number of subjects: 2
Study 34643538 — intervention group
Group type: EXPERIMENTAL
Intervention: CONEMO plus enhanced usual care
Number of subjects: 1312
Study 34643538 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 1312
Study 34643541 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supportive text messaging for 6 months
Number of subjects: 0
Study 34643541 — intervention group
Group type: COMPARATOR
Intervention: Daily supportive email messaging for 6 months
Number of subjects: 0
Study 34643612 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34643690 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-MRD (mass spectrometry minimal residual disease)
Number of subjects: 41
Study 34643690 — intervention group
Group type: COMPARATOR
Intervention: NGS-MRD (next-generation sequencing minimal residual disease)
Number of subjects: 41
Study 34643690 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-MRD and NGS-positive patients
Number of subjects: 41
Study 34643690 — intervention group
Group type: COMPARATOR
Intervention: NGS-negative patients
Number of subjects: 41
Study 34643690 — intervention group
Group type: COMPARATOR
Intervention: MS-negative patients
Number of subjects: 41
Study 34643690 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD-negative patients for both methods
Number of subjects: 41
Study 34643690 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-MRD relapse during maintenance treatment
Number of subjects: 41
Study 34643894 — intervention group
Group type: EXPERIMENTAL
Intervention: Presbyopia Impact and Coping Questionnaire (PICQ)
Number of subjects: 151
Study 34643895 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 27
Study 34643949 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge planning (BP)
Number of subjects: 86
Study 34643949 — intervention group
Group type: COMPARATOR
Intervention: No binge planning (non-BP)
Number of subjects: 86
Study 34644145 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided focused ultrasound (MRgFUS) combined with intravenous trastuzumab-based therapies
Number of subjects: 4
Study 34644385 — intervention group
Group type: EXPERIMENTAL
Intervention: Antilymphoma treatment including anti-CD20 containing regimens
Number of subjects: 856
Study 34644385 — intervention group
Group type: EXPERIMENTAL
Intervention: Hodgkin's lymphoma
Number of subjects: 856
Study 34644385 — intervention group
Group type: EXPERIMENTAL
Intervention: Time interval between lymphoma diagnosis and COVID-19
Number of subjects: 856
Study 34644385 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, gender, lymphocyte, and platelet count (multivariable analysis factors)
Number of subjects: 856
Study 34644385 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 856
Study 34644444 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived stem cells (GXNPC1)
Number of subjects: 3
Study 34644605 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidative hematopoietic cell transplantation (HCT) after CD19 CAR T cell therapy
Number of subjects: 50
Study 34644605 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidative HCT after CAR T cell therapy
Number of subjects: 50
Study 34644605 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidative HCT for subjects with CAR T cell functional persistence of 63 days or less
Number of subjects: 50
Study 34644605 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 50
Study 34644735 — intervention group
Group type: EXPERIMENTAL
Intervention: hu3S193 antibody administration at weekly intravenous doses of 20 mg/m2 for 8-week cycles
Number of subjects: 22
Study 34645283 — intervention group
Group type: EXPERIMENTAL
Intervention: Andexanet alfa
Number of subjects: 182
Study 34645283 — intervention group
Group type: COMPARATOR
Intervention: Usual care (prothrombin complex concentrates)
Number of subjects: 182
Study 34645283 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 182
Study 34645285 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital improvement
Number of subjects: 1588
Study 34645285 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital worsening
Number of subjects: 1588
Study 34645285 — intervention group
Group type: COMPARATOR
Intervention: No fluctuations
Number of subjects: 1588
Study 34645381 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 0
Study 34645381 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study 34645381 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 0
Study 34645381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0
Study 34645381 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 0
Study 34645390 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning (ML) analysis of ECG patterns
Number of subjects: 300
Study 34645390 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptomic analysis
Number of subjects: 300
Study 34645390 — intervention group
Group type: EXPERIMENTAL
Intervention: ML algorithm testing
Number of subjects: 300
Study 34645390 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-BrS patients)
Number of subjects: 300
Study 34645474 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopoietin-1
Number of subjects: 0
Study 34645490 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Action Process Approach (HAPA) intervention
Number of subjects: 56
Study 34645490 — intervention group
Group type: COMPARATOR
Intervention: Standardised care (SC)
Number of subjects: 56
Study 34645490 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires assessing risk perception, outcome expectancy, self-efficacy (SEMSA), quality of sleep (PSQI and ESS), quality of life (EQ-5DL), socio-economic and social support scales
Number of subjects: 56
Study 34645512 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led transitional burns rehabilitation programme (4Cs-TBuRP)
Number of subjects: 150
Study 34645512 — intervention group
Group type: COMPARATOR
Intervention: Routine post-discharge service
Number of subjects: 150
Study 34645514 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of blue dye and a radioactive isotope in the stumps of the ligamentum ovarium proprium and the ligamentum infundibulo-pelvicum.
Number of subjects: 11
Study 34645514 — intervention group
Group type: COMPARATOR
Intervention: Injection of tracer in the ovarian ligaments before tumor resection.
Number of subjects: 11
Study 34645616 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Questionnaire-Brief (DSMQ-Brief) scores at T1, T2, and T3
Number of subjects: 127
Study 34645616 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Family Conflict Scale-Revised (DFCS-R) scores
Number of subjects: 127
Study 34645616 — intervention group
Group type: EXPERIMENTAL
Intervention: Child HbA1c values at T1, T2, and T3
Number of subjects: 127
Study 34645648 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib (225 mg twice daily on days 1-3, 8-10, and 15-17) plus carboplatin every 21 days
Number of subjects: 94
Study 34645648 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib (various dosages) combined with chemotherapy agents (gemcitabine, paclitaxel, carboplatin, pegylated liposomal doxorubicin)
Number of subjects: 94
Study 34645648 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib (various dosages)
Number of subjects: 94
Study 34645704 — intervention group
Group type: EXPERIMENTAL
Intervention: EmboTrap device as the first attempted device
Number of subjects: 1000
Study 34645790 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC Complex I+III and IV activity in ASD participants
Number of subjects: 18
Study 34645790 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative elevation in Complex IV activity in ASD participants
Number of subjects: 18
Study 34645790 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference between ETC Complex I+III and IV activity
Number of subjects: 18
Study 34645790 — intervention group
Group type: COMPARATOR
Intervention: Fibroblasts derived from ASD participants
Number of subjects: 18
Study 34645820 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiome of allergic children
Number of subjects: 120
Study 34645820 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiome signatures at baseline
Number of subjects: 120
Study 34645820 — intervention group
Group type: EXPERIMENTAL
Intervention: R. gnavus strains enriched in FA and RA
Number of subjects: 120
Study 34645820 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiome dysbiosis in allergic children
Number of subjects: 120
Study 34645820 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (CT)
Number of subjects: 120
Study 34646387 — intervention group
Group type: EXPERIMENTAL
Intervention: Onvansertib (Polo-like kinase 1 inhibitor)
Number of subjects: 0
Study 34646440 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct low-dose aripiprazole (5 mg) added to current antipsychotic for 12 weeks
Number of subjects: 0
Study 34646853 — intervention group
Group type: EXPERIMENTAL
Intervention: High Glycemic Diet
Number of subjects: 0
Study 34646853 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34647444 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab plus carfilzomib and dexamethasone (Isa-Kd)
Number of subjects: 0
Study 34647444 — intervention group
Group type: COMPARATOR
Intervention: Carfilzomib and dexamethasone (Kd)
Number of subjects: 0
Study 34647513 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal nerve stimulation (RNS) during renal sympathetic denervation (RDN)
Number of subjects: 44
Study 34647513 — intervention group
Group type: EXPERIMENTAL
Intervention: RNS before RDN
Number of subjects: 44
Study 34647513 — intervention group
Group type: EXPERIMENTAL
Intervention: RNS after RDN
Number of subjects: 44
Study 34647513 — intervention group
Group type: COMPARATOR
Intervention: Complete denervation
Number of subjects: 44
Study 34647513 — intervention group
Group type: EXPERIMENTAL
Intervention: RNS-induced BP changes
Number of subjects: 44